HRP20191723T1 - Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa - Google Patents

Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa Download PDF

Info

Publication number
HRP20191723T1
HRP20191723T1 HRP20191723T HRP20191723T1 HR P20191723 T1 HRP20191723 T1 HR P20191723T1 HR P20191723 T HRP20191723 T HR P20191723T HR P20191723 T1 HRP20191723 T1 HR P20191723T1
Authority
HR
Croatia
Prior art keywords
oligonucleotide
subject
preparation
weeks
single exposure
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Charlotte Admyre
Arezou Zargari
Stein Oliver Von
Stein Petra Von
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Publication of HRP20191723T1 publication Critical patent/HRP20191723T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20191723 2011-11-25 2012-11-23 Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa HRP20191723T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11190826.5A EP2596806A1 (en) 2011-11-25 2011-11-25 Method for prevention of colectomy
US201261595230P 2012-02-06 2012-02-06
PCT/EP2012/073501 WO2013076262A1 (en) 2011-11-25 2012-11-23 Method for prevention of colectomy
EP12790904.2A EP2782602B1 (en) 2011-11-25 2012-11-23 Nucleotide DIMS0-150 for use in the treatment of chronic active ulcerative colitis

Publications (1)

Publication Number Publication Date
HRP20191723T1 true HRP20191723T1 (hr) 2019-12-13

Family

ID=45094516

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191723 HRP20191723T1 (hr) 2011-11-25 2012-11-23 Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa

Country Status (16)

Country Link
US (3) US9492516B2 (enExample)
EP (3) EP2596806A1 (enExample)
JP (2) JP6193248B2 (enExample)
CA (1) CA2892203C (enExample)
CY (1) CY1122089T1 (enExample)
DK (1) DK2782602T3 (enExample)
ES (1) ES2745677T3 (enExample)
HR (1) HRP20191723T1 (enExample)
HU (1) HUE046154T2 (enExample)
LT (1) LT2782602T (enExample)
PL (1) PL2782602T3 (enExample)
PT (1) PT2782602T (enExample)
RS (1) RS59358B1 (enExample)
SI (1) SI2782602T1 (enExample)
SM (1) SMT201900527T1 (enExample)
WO (1) WO2013076262A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102040448B1 (ko) * 2013-07-05 2019-11-04 새턴 라이센싱 엘엘씨 송신 장치 및 송신 방법, 및 수신 장치 및 수신 방법
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
IL269970B (en) 2017-04-14 2022-09-01 Tallac Therapeutics Inc Polynucleotides that modulate the immune system, their antibody binding, and methods of using them
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201807312D0 (en) 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201818579D0 (en) * 2018-11-14 2018-12-26 Index Pharmaceuticals Ab New therapy
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
DK0772619T4 (da) 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
WO1997028259A1 (en) 1996-01-30 1997-08-07 The Regents Of The University Of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US6610661B1 (en) 1996-10-11 2003-08-26 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
CA2594730A1 (en) 2005-01-13 2006-07-20 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
CA2614295A1 (en) * 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
US8148341B2 (en) 2005-07-01 2012-04-03 Index Pharmaceuticals Ab Method for modulating responsiveness to steroids
EP1901759B1 (en) 2005-07-01 2010-08-04 Index Pharmaceuticals AB Immunostimulatory method
US8637479B2 (en) * 2008-11-04 2014-01-28 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS

Also Published As

Publication number Publication date
LT2782602T (lt) 2019-10-10
RS59358B1 (sr) 2019-11-29
PL2782602T3 (pl) 2019-12-31
CA2892203C (en) 2021-11-16
SI2782602T1 (sl) 2019-11-29
EP3556403A1 (en) 2019-10-23
US20180015117A1 (en) 2018-01-18
JP2015504438A (ja) 2015-02-12
JP6193248B2 (ja) 2017-09-06
JP6318221B2 (ja) 2018-04-25
WO2013076262A1 (en) 2013-05-30
SMT201900527T1 (it) 2019-11-13
CY1122089T1 (el) 2020-11-25
EP2782602A1 (en) 2014-10-01
JP2017061508A (ja) 2017-03-30
CA2892203A1 (en) 2013-05-30
US9795627B2 (en) 2017-10-24
EP2596806A1 (en) 2013-05-29
US20150004187A1 (en) 2015-01-01
US9492516B2 (en) 2016-11-15
ES2745677T3 (es) 2020-03-03
PT2782602T (pt) 2019-10-14
DK2782602T3 (da) 2019-09-30
US20170014442A1 (en) 2017-01-19
EP2782602B1 (en) 2019-06-26
HUE046154T2 (hu) 2020-02-28

Similar Documents

Publication Publication Date Title
HRP20191723T1 (hr) Nukleotid dims0-150 za primjenu u liječenju kroničnog aktivnog ulceroznog kolitisa
HRP20191957T1 (hr) Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba
HRP20180237T4 (hr) Metode za liječenje hcv-a
MY161593A (en) Oral formulations of cytidine analogs and methods of use thereof
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
JP2015504438A5 (enExample)
JP2015038135A5 (enExample)
MX357551B (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
JP2013231087A5 (enExample)
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
BR112013022044A2 (pt) veículo mastigável para absorção na boca
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
PH12014500386A1 (en) Combination treatment for hepatitis c
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
WO2011151722A3 (en) Methods and compositions for oral pharmaceutical therapy
HRP20191348T1 (hr) Aminosteroidi za liječenje bolesti povezanih s ptp1b
JP2017512194A5 (enExample)
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
AR093476A1 (es) Composiciones y metodos para el tratamiento de la displasia ectodermica
HRP20250972T1 (hr) Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak